pirfenidone has been researched along with Body Weight in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, YJ; Kim, HJ; Kim, TH; Kim, YW; Kwon, BS; Lee, CT; Lee, JH; Lee, YJ; Lim, SY; Park, JS; Shin, YY; Song, MJ | 1 |
| Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M | 1 |
| Serrya, MS; Sharawy, MH | 1 |
| Ghazi-Khansari, M; Heidari, MR; Iranpour, M; Mandegary, A; Pourgholamhossein, F; Pourgholi, L; Pournamdari, M; Poursalehi, HR; Rasooli, R; Samareh-Fekri, M | 1 |
| Li, L; Liu, B; Qin, W; Tang, Y; Wu, B; Yi, M; Yuan, X | 1 |
| Hanatani, A; Iwao, H; Izumi, Y; Muro, T; Nakamura, Y; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Bao, L; Cho, IH; Hyun, BH; Kim, YJ; Lee, CH; Margolin, SB; Park, HS; Park, YH | 1 |
| Al-Bayati, MA; Du, X; Giri, SN; Margolin, SB; Mohr, FC; Schelegle, E | 1 |
| Giri, SN; Hyde, DM; Iyer, SN; Margolin, SB; Schiedt, MJ; Wild, JS | 1 |
| Furutani, S; Komemushi, S; Margolin, S; Ota, K; Suga, H; Teraoka, S; Yamauchi, S | 1 |
| Giri, S; Mansoor, JK; Schelegle, ES | 1 |
| Fukagawa, M; Hata, S; Iwasaki, Y; Kuroda, T; Kurokawa, K; Margolin, SB; Nemoto, M; Shimizu, F; Shimizu, T; Shirai, K; Yamauchi, S | 1 |
| Fukagawa, M; Hata, S; Kuroda, T; Kurokawa, K; Margolin, SB; Shimizu, T | 1 |
| Bloom, RF; Margolin, SB; Shetlar, CL; Shetlar, DJ; Shetlar, MR | 1 |
| Enjoji, M; Iwamoto, H; Kato, M; Nakamuta, M; Nakashima, Y; Nawata, H; Sugimoto, R; Tada, S | 1 |
| Brown, L; Dallemagne, C; Endre, Z; Margolin, S; Miric, G; Taylor, SM | 1 |
16 other study(ies) available for pirfenidone and Body Weight
| Article | Year |
|---|---|
Impact of body weight change on clinical outcomes in patients with idiopathic pulmonary fibrosis receiving pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Carbon Monoxide; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Retrospective Studies; Treatment Outcome; Vital Capacity; Weight Loss | 2022 |
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation | 2021 |
Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats.
Topics: Acute Kidney Injury; Animals; Body Weight; Chemokine CCL2; Gentamicins; Inflammasomes; Kidney Function Tests; L-Lactate Dehydrogenase; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Protective Agents; Pyridones; Rats, Wistar; Toll-Like Receptor 4 | 2020 |
Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bronchoalveolar Lavage Fluid; Fibrosis; Gene Expression; Gene Expression Profiling; Herbicides; Hydroxyproline; Lung; Lung Injury; Male; Mice; Organ Size; Oxidative Stress; Paraquat; Pneumonia; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1 | 2018 |
Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model.
Topics: Animals; Body Weight; Collagen; Disease Models, Animal; Female; Kaplan-Meier Estimate; Longevity; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Radiation, Ionizing; Radiotherapy; Signal Transduction; Transforming Growth Factor beta1 | 2018 |
The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Cardiomegaly; Fibrosis; Heart; Heart Rate; Hypertension; Male; Mice; Mice, Inbred BALB C; Myocardium; Pyridones | 2012 |
Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis; Kidney; Kidney Diseases; Male; Mice; Proteinuria; Pyridones; Sclerosis; Time Factors | 2003 |
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Body Weight; Diet; Doxorubicin; Eating; Heart Diseases; Hemodynamics; Kidney; Kidney Diseases; Male; Myocardium; Pyridones; Rats; Rats, Sprague-Dawley; Respiratory Function Tests | 2004 |
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.
Topics: Analysis of Variance; Animals; Bleomycin; Body Weight; Cricetinae; Diet; Hydroxyproline; Lipid Peroxidation; Lung; Male; Mesocricetus; Peroxidase; Procollagen-Proline Dioxygenase; Pulmonary Fibrosis; Pyridones; Superoxide Dismutase | 1995 |
Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chlorhexidine; Fibrosis; Intestines; Liver; Male; Peritonitis; Pyridones; Rats; Rats, Wistar; Sclerosis | 1995 |
Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Body Weight; Cardiovascular System; Cricetinae; Hydroxyproline; Lung; Male; Pulmonary Fibrosis; Pyridones; Respiration; Respiratory Function Tests | 1997 |
Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northern; Body Weight; Collagen; Creatinine; Fibrosis; Hydroxyproline; Kidney; Male; Nephrectomy; Pyridones; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta | 1997 |
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Collagen; Disease Models, Animal; Fibrosis; Gelatinases; Hydroxyproline; Inulin; Kidney Cortex; Kidney Function Tests; Ligation; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Transforming Growth Factor beta; Ureter; Ureteral Obstruction | 1998 |
Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cell Transplantation; Electrophoresis, Cellulose Acetate; Female; Glucocorticoids; Glycosaminoglycans; Humans; Keloid; Male; Mice; Mice, Nude; Middle Aged; Pyridones; Triamcinolone | 1998 |
Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.
Topics: Animals; Blotting, Northern; Body Weight; Collagen; Dimethylnitrosamine; Hydroxyproline; Liver Cirrhosis; Male; Pyridones; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta | 2001 |
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calcium Chloride; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drinking; Eating; Fibrosis; Glomerular Filtration Rate; Heart Ventricles; In Vitro Techniques; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Quinolines; Rats; Rats, Wistar; Spironolactone; Thiadiazines; Vasoconstriction; Vasoconstrictor Agents | 2001 |